Clinical Reminders in Test Reports to Improve Guideline Compliance

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00414401
First received: December 19, 2006
Last updated: February 6, 2014
Last verified: December 2006
  Purpose

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.


Condition Intervention
Heart Failure, Congestive
Behavioral: Clinical Reminder

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Clinical Reminders in Test Reports to Improve Guideline Compliance

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Prescription for any beta-blocker [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Prescription for carvedilol or metoprolol succinate [ Designated as safety issue: No ]

Estimated Enrollment: 1500
Study Start Date: May 2001
Study Completion Date: June 2006
Arms Assigned Interventions
Arm 1 Behavioral: Clinical Reminder

Detailed Description:

Background:

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Objectives:

To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function.

Methods:

We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography

Status:

The project is complete.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Those undergoing echocardiography at one of the participating laboratories with an ejection fraction < 45%.

Exclusion Criteria:

aortic stenosis, mitral stenosis

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00414401

Locations
United States, California
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304-1207
Sponsors and Collaborators
Investigators
Principal Investigator: Paul A. Heidenreich, MD MS VA Palo Alto Health Care System
  More Information

Publications:
Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00414401     History of Changes
Other Study ID Numbers: IIR 01-108
Study First Received: December 19, 2006
Last Updated: February 6, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 22, 2014